Tisento Therapeutics
CompanyUnited States
Tisento Therapeutics develops one asset, in phase 2 (zagociguat in mitochondrial encephalopathy, lactic acidosis and stroke-like episodes). Mostly small molecule acting on oxidative phosphorylation, Mitochondrial biogenesis (PGC-1α) and GUCY1A1; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 0
- Signals
Pipeline
1CNS-penetrant soluble guanylate cyclase (sGC) stimulator
Phase 2, Small molecule, Oxidative phosphorylation, Mitochondrial biogenesis (PGC-1α), mitochondrial encephalopathy, lactic acidosis and stroke-like episodes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials1
- Similar companies6